Please login to the form below

Not currently logged in
Email:
Password:

V Bryan Lawlis joins board of KaloBios

Is co-founder of Itero and Covance

KaloBios has announced that Dr V Bryan Lawlis is to join the company's board of directors.

Dr Lawlis is current president and CEO of Itero Biopharmaceuticals and is a director at several other life sciences companies including Biomarin Pharmaceutical, Geron, and Sutro Biopharmaceuticals.

He has entrepreneurial experience, co-founding Itero in 2006 and contract manufacturing firm Covance Biotechnology Services in 1996.

Other previous roles include CEO of Aradigm Corporation, VP of process sciences at Genetech.

His extensive industry knowledge and drug development experience, especially in the manufacturing of therapeutic proteins and antibodies, will serve KaloBios well as we advance the development of our portfolio of proprietary, patient-targeted, monoclonal antibodies towards commercialisation,” said David Pritchard, president and CEO of KaloBios.

This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.

9th August 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics